Compugen (Compugen) Issuance of Debt : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Compugen Issuance of Debt?

Compugen's Issuance of Debt for the three months ended in Dec. 2023 was $0.00 Mil.

Compugen's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Compugen Issuance of Debt Historical Data

The historical data trend for Compugen's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Issuance of Debt Chart

Compugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Issuance of Debt

Get a 7-Day Free Trial

Compugen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Compugen Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Compugen Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Compugen's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Compugen (Compugen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (NAS:CGEN) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

CGEN:Israel

Address

26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849

Website

https://www.cgen.com

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.